Chiauranib for Advanced Cancers
(SCLC Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing a new drug called chiauranib for patients with advanced cancers that don't respond to standard treatments. It aims to block the signals that cancer cells need to grow. The focus is on patients with small cell lung cancer that has worsened after previous treatments.
Will I have to stop taking my current medications?
The trial requires that you stop taking any systemic anticancer therapy at least 21 days before joining. If you are on strong CYP3A4 inhibitor or inducer drugs, you will need to stop those as well during the dose escalation stage. Other medications are not specifically mentioned, so it's best to discuss with the trial team.
What makes the drug Chiauranib unique for treating advanced cancers?
Chiauranib is unique because it is an oral drug that targets multiple pathways involved in cancer growth, including those related to blood vessel formation (angiogenesis), cell division (mitosis), and inflammation. This multi-target approach, particularly its inhibition of VEGFR2 and the ERK/STAT3 signaling pathway, makes it a promising option for cancers with no efficient treatment strategies, like transformed follicular lymphoma.12345
Eligibility Criteria
This trial is for adults with advanced solid tumors or relapsed/refractory Small Cell Lung Cancer (SCLC) who have measurable disease progression. Participants must be in good physical condition (ECOG 0-1), have proper organ function, and a life expectancy that allows participation. Women of childbearing age and men must agree to use effective contraception during the study and for some time after.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose-Escalation
Participants undergo dose-escalation with chiauranib in 3 cohorts (35 mg, 50 mg, 65 mg) to determine the maximum tolerated dose and recommended Phase 2 dose.
Treatment
Participants receive the recommended Phase 2 dose of chiauranib once daily in 28-day cycles continuously with no interruption.
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of adverse events and survival outcomes.
Treatment Details
Interventions
- Chiauranib (Tyrosine Kinase Inhibitor)